Frankfurt - Delayed Quote EUR

MPH Health Care AG (93M1.F)

19.50 -0.50 (-2.50%)
At close: April 19 at 9:52 AM GMT+2
Loading Chart for 93M1.F
DELL
  • Previous Close 20.00
  • Open 19.50
  • Bid 21.00 x --
  • Ask 21.80 x --
  • Day's Range 19.50 - 19.50
  • 52 Week Range 13.65 - 25.50
  • Volume 2,860
  • Avg. Volume 106
  • Market Cap (intraday) 83.487M
  • Beta (5Y Monthly) 1.05
  • PE Ratio (TTM) 1.68
  • EPS (TTM) 11.61
  • Earnings Date Apr 25, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date Jul 18, 2019
  • 1y Target Est --

MPH Health Care AG, an investment company, engages in the healthcare business in Germany. It produces and sells medicinal products for the therapies of cancer, HIV, and other chronic diseases. The company also offers medical aesthetic treatments; and develops and sells pharmaceutical and medical products; and provides related services, as well as medical devices for the aesthetic surgery and cosmetic dermatology. In addition, it is involved in the provision of cytostatic solutions; and real estate activities. The company was formerly known as MPH Mittelständische Pharma Holding AG and changed its name to MPH Health Care AG in 2017. The company was founded in 2008 and is based in Berlin, Germany.

www.mph-ag.de

1

Full Time Employees

December 31

Fiscal Year Ends

Related News

Performance Overview: 93M1.F

Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

93M1.F
18.90%
DAX PERFORMANCE-INDEX
5.88%

1-Year Return

93M1.F
43.91%
DAX PERFORMANCE-INDEX
11.68%

3-Year Return

93M1.F
34.34%
DAX PERFORMANCE-INDEX
14.73%

5-Year Return

93M1.F
52.33%
DAX PERFORMANCE-INDEX
45.12%

Compare To: 93M1.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 93M1.F

Valuation Measures

As of 4/19/2024
  • Market Cap

    85.63M

  • Enterprise Value

    82.26M

  • Trailing P/E

    1.72

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    12.96

  • Price/Book (mrq)

    0.42

  • Enterprise Value/Revenue

    12.45

  • Enterprise Value/EBITDA

    1.63

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    161.79%

  • Return on Assets (ttm)

    9.71%

  • Return on Equity (ttm)

    27.43%

  • Revenue (ttm)

    30.72M

  • Net Income Avi to Common (ttm)

    49.7M

  • Diluted EPS (ttm)

    11.61

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.38M

  • Total Debt/Equity (mrq)

    1.51%

  • Levered Free Cash Flow (ttm)

    14.3M